Related Experiment Video

Updated: Jun 1, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K

CDK4/6 Inhibitor Resistance in ER+ Breast Cancer

Ilenia Migliaccio1, Cristina Guarducci1, Luca Malorni2

  • 1Translational Research Unit, Hospital of Prato, AUSL Toscana Centro, Prato, Italy.

Advances in Experimental Medicine and Biology
|January 17, 2025
PubMed

Insights

Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors improve outcomes for hormone receptor-positive breast cancer. Understanding and overcoming resistance mechanisms is crucial for enhancing treatment efficacy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors are standard treatment for hormone receptor-positive (HR+), HER2-negative breast cancer.
  • These inhibitors have demonstrated efficacy in both metastatic and early-stage settings.
  • Acquired or de novo resistance to CDK4/6 inhibitors presents a significant clinical challenge.

Purpose of the Study:

  • To review the current understanding of CDK4/6 inhibitor mechanisms of action.
  • To summarize efficacy data for CDK4/6 inhibitors in breast cancer treatment.
  • To explore the known mechanisms of resistance to CDK4/6 inhibitors.

Main Methods:

  • Literature review of preclinical and clinical studies on CDK4/6 inhibitors.
  • Analysis of data on patient selection, treatment outcomes, and resistance patterns.
  • Investigation of cell cycle-related gene and protein alterations as resistance markers.

Main Results:

  • CDK4/6 inhibitors target cell cycle progression, improving outcomes in HR+/HER2- breast cancer.
  • Resistance mechanisms, including alterations in cell cycle pathways, are being actively investigated.
  • Current treatment decisions for CDK4/6 inhibitors rely solely on HR and HER2 status.

Conclusions:

  • CDK4/6 inhibitors are effective but resistance limits long-term benefit.
  • Identifying predictive biomarkers and understanding resistance mechanisms are key to developing next-generation therapies.
  • Further research is needed to overcome resistance and optimize treatment strategies for breast cancer patients.
Keywords:
BiomarkersBreast cancerCDK4/6 inhibitorsCell cycleResistance

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.3K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K